1
Ashok R Amin, Steven B Abramson, Lorne M Golub, Nungavaram S Ramamurthy, Thomas F McNamara, Robert A Greenwald, Howard Trachtman: Method of using tetracycline compounds for inhibition of endogenous nitric oxide production. The Research Foundation of State University of New York, Hospital for Joint Diseases, Hoffmann & Baron, August 4, 1998: US05789395 (107 worldwide citation)

A method is disclosed for inhibiting endogenous production of nitric oxide (NO) in an in vivo, in vitro, or ex vivo mammalian system. The method employs a tetracycline compound to inhibit production of NO and/or to inhibit the expression or activity of an inducible isoform of nitric oxide synthase ( ...


2
Lorne M Golub, Nungavarum S Ramamurthy, Thomas F McNamara, Maria E Ryan: Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive glycosylation of different types of collagen and other proteins during diabetes. The Research Foundation of State University of New York, Hoffmann & Baron, July 2, 1996: US05532227 (102 worldwide citation)

A method for treating mammals suffering from excessive extracellular protein glycosylation which is associated with diabetes, scleroderma and progeria by administering to the mammal a tetracycline which effectively inhibits excessive protein glycosylation.


3
Lorne M Golub, Thomas F McNamara, N S Ramamurthy: Inhibition of mammalian collagenolytic enzymes by tetracyclines. Research Foundation of State University, Omri M Behr, May 19, 1987: US04666897 (80 worldwide citation)

A method of reducing pathologically excessive levels of activity of collagenolytic enzymes in mammals to substantially normal levels by administering 10-100% of the normal antibiotic therapeutic dose of a tetracycline is disclosed.


4
Thomas F McNamara, Lorne M Golub, Nungavaram S Ramamurthy: Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis. The Research Foundation of State University of New York, Cooper & Dunham, May 15, 1990: US04925833 (71 worldwide citation)

Tetracyclines, antibacterial and non-antibacterial tetracyclines, have been found to be useful in the treatment of osteoporosis in humans by administering to the human suffering from osteoporosis an effective amount of a tetracycline to enhance bone protein synthesis. Tetracyclines which have been f ...


5
Waldemar Pruzanski, Lorne M Golub, Peter Vadas, Robert A Greenwald, Nangavarum S Ramamurthy, Thomas F McNamara: Inhibition of excessive phospholipase A.sub.2 activity and/or production by non-antimicrobial tetracyclines. The Research Foundation of State Univ of New York, Hoffman & Baron, March 28, 2000: US06043231 (68 worldwide citation)

A method for treating mammals suffering from conditions associated with excess phospholipase A.sub.2 activity and/or production comprising administering to the mammal an effective amount of a non-antimicrobial tetracycline sufficient to inhibit excess phospholipase A.sub.2 activity and/or production ...


6
Thomas F McNamara, Nungavaram S Ramamurthy, Lorne M Golub: Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same. The Research Foundation of State University of New York, Cooper Dunham Griffin & Moran, November 3, 1987: US04704383 (66 worldwide citation)

Tetracyclines having substantially no effective antibiotic or antibacterial activity and possessing anti-collagen-destructive enzyme activity or anti-collagenase activity and compositions containing the same have been found useful as anti-collagenolytic agents. Such tetracyclines and compositions co ...


7
Thomas F McNamara, Nungavaram S Ramamurthy, Lorne M Golub: Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same. The Research Foundation of State University of New York, Cooper & Dunham, June 19, 1990: US04935412 (65 worldwide citation)

Tetracyclines having substantially no effective antibiotic or antibacterial activity and possessing anti-collagen-destructive enzyme activity or anti-collagenase activity and compositions containing the same have been found useful as anti-collagenolytic agents. Such tetracyclines and compositions co ...


8
Lorne M Golub, Nangavarum S Ramamurthy, Thomas F McNamara, Robert A Greenwald, Tsutomu Kawai, Takashi Hamasaki, Michiya Shimamura, Goro Kobayashi, Tetsuo Takigawa, Hisashi Iwata: Method to reduce connective tissue destruction. Kuraray, Hoffmann & Baron, November 2, 1993: US05258371 (62 worldwide citation)

Provided is a method of treating humans or animals suffering from a condition or disease characterized by excessive collagen destruction, which comprises administering to said human or animal an effective amount of a 12a-deoxytetracycline represented by the following general formula ##STR1## The met ...


9
Lorne M Golub, Nangavarum S Ramamurthy, Thomas F McNamara, Robert A Greenwald: Composition comprising indomethacin [non-steroidal anti-inflammatory agent] and effectively non-antibacterial tetracycline to reduce bone loss. The Research Foundation of State University of New York, Hoffmann & Baron, October 17, 1995: US05459135 (52 worldwide citation)

A method for treating mammals suffering from rheumatoid arthritis and other tissue-destructive (chronic inflammatory or other) conditions associated with excess metalloproteinase activity comprising administering to the mammal an amount of a tetracycline that is effectively anti-metalloproteinase, b ...


10
Waldemar Pruzanski, Lorne M Golub, Peter Vadas, Robert A Greenwald, Nangavarum S Ramamurthy, Thomas F McNamara: Inhibition of excessive phospholipase A.sub.2 activity and/or production by non-antimicrobial tetracyclines. The Research Foundation of State University of New York, Hoffmann & Baron, June 4, 1996: US05523297 (52 worldwide citation)

A method for treating mammals suffering from conditions associated with excess phospholipase A.sub.2 activity and/or production comprising administering to the mammal an effective amount of a non-antimicrobial tetracycline sufficient to inhibit excess phospholipase A.sub.2 activity and/or production ...